February 28, 2017 / 12:40 PM / 6 months ago

Kite Pharma's cancer drug clears main goal in study

Feb 28 (Reuters) - Kite Pharma Inc said on Tuesday its experimental CAR T-cell therapy, which helps the immune system fight cancer, was highly effective in treating aggressive non-Hodgkin lymphoma, meeting the main goal of a pivotal study.

CAR T-cell drugs are made by genetically altering a patients' own T-cells to add a component of antibodies that makes them better able to spot and kill cancer cells.

Non-Hodgkin Lymphoma occurs when the body produces too many abnormal lymphocytes, a type of white blood cell. Symptoms include swollen lymph nodes, fever, night sweats, chest pain and loss of appetite. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Savio D'Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below